The nephrologist's role in the management of calcium-phosphoWhile the importance of nephrologist care for patients rus metabolism in patients with chronic kidney disease.
While the importance of nephrologist care for patients rus metabolism in patients with chronic kidney disease.
with end-stage renal disease (ESRD) is evident, their
Background. In patients with chronic kidney disease (CKD), role in the care of patients with chronic kidney disease timely referral to a nephrologist has been shown to improve (CKD) is only vaguely defined. A growing body of literaoutcomes, but the specific care measures mediating these supeture has demonstrated that timely nephrologist referral rior outcomes have not been sufficiently described.
Methods. In a cohort of 3014 patients with CKD, we evaluof patients with CKD is associated with higher quality ated whether they had any indicators of calcium-phosphorus of care during the transition from CKD to renal replacemetabolism management prior to renal replacement therapy ment therapy (RRT) [1] [2] [3] [4] [5] [6] , and with improved outcomes (RRT) . These included measurement of parathyroid hormone on RRT [7] [8] [9] [10] [11] [12] . However, none of these studies has de-(PTH) or vitamin D metabolites, or receipt of calcitriol or calcium-containing phosphate binders (CCPB) prior to RRT.
fined the specific measures nephrologists initiate that led
Control patients without such care were selected by risk-set to these improved outcomes.
matching. We used multivariate conditional logistic regression
Several aspects of the care of patients with CKD can analysis to test whether use of these interventions was associbe speculated to mediate the better outcomes seen with ated with prior nephrologist consultation. We then used Cox early nephrologist care: better assessment and manageproportional hazards models to assess whether implementation of such care was associated with differences in 1-year mortality ment of renal anemia, blood pressure, malnutrition, or once RRT was instituted.
disturbances of the calcium-phosphorus metabolism.
Results. Only 3.4% of CKD patients had their PTH assessed
This study focuses on the latter aspect of CKD care.
prior to RRT, and 0.3% had vitamin D status measured. Use of Changes in calcium-phosphorus metabolism occur relcalcitriol (12.2%) and CCPBs (16%) was slightly more prevalent. Seeing a nephrologist was highly associated with use of the tests atively early during the course of CKD [13] and manifest and drugs studied (odds ratio, test or filled prescription (ϭ case), the earliest procedure To evaluate the role of nephrologists in managing this code was labeled as the index claim, and the number of specific domain of care for patients with CKD, we sought days prior to RRT was recorded. Next, we identified up to test whether such management occurred more freto 5 CKD controls who had not received the correspondquently in patients seen by a nephrologist controlling ing laboratory test or filled the prescription at the same for other health care utilization patterns as well as demonumber of days prior to RRT and matched them for age graphic characteristics and renal and nonrenal comorbidwith each case (risk-set matching) [33] . In each risk set ities. The interventions studied were assessment of iPTH,
(1 case, Յ5 controls), we assessed whether these patients measurement of serum levels of vitamin D and/or its had seen a nephrologist on or within 30 days of the index metabolites, and prescriptions for calcitriol and for caldate. We did so by searching for presence of specific cium-containing phosphate binders (CCPBs). We next adspecialty codes for nephrology associated with medical dressed whether such care might help to explain changes claims. Similarly, we ascertained the number of general seen in mortality in the first year of RRT.
practitioner or family physician visits in Յ30 days prior to index, the number of visits with internal medicine METHODS specialists, as well as the number of hospital days during We studied a cohort of 3014 incident RRT patients that time window. enrolled in Medicare and in the New Jersey PharmaceuOther covariates describing important comorbidities tical Assistance to the Aged and Disabled (PAAD) or were ascertained in a 90-day window: diabetes, hypertenNew Jersey Medicaid programs between 1991 and midsion, coronary heart disease, congestive heart failure, 1996. Patients were required to have been enrolled and malignancy, and polycystic kidney disease. Race (Caucaactive participants in these programs for more than 1 sian, African American, other) and gender were also year prior to onset of RRT, and to have been diagnosed assessed. For the drug-related analyses, we required that with CKD Ͼ1 year prior to RRT, to ensure that they at least one prescription had been filled in the 30 days progressed to ESRD chronically rather than acutely.
prior to the index date, as well as Ͼ30 days prior to the Further selection steps were implemented to exclude index date to ensure that all subjects used were active patients with likely acute renal failure from the cohort.
in the system. All patient identifiers were removed prior to analysis to For each set of analyses, we then built conditional ensure patient confidentiality. The details of the selection logistic regression models, stratifying by risk set, with algorithm have been published previously [31] . We then use of the respective laboratory test or prescription drug extracted information on all hospitalizations, physician being the outcome. Independent covariates included prior nephrologist consultation, the other health care utilizavisits, procedures, and nursing home care received by the 3014 patients in the full cohort, we found that 102 patients (3.4%) had iPTH measured prior to onset of RRT, and only 10 patients (0.3%) had undergone laboratory assessment of blood levels of vitamin D or its metabtion covariates (general practitioner visit, internist visit, olites. In the subgroup of patients with pharmaceutical hospital days), as well as race, gender, and the indicators benefits through the New Jersey PAAD or Medicaid programs (N ϭ 1004), 161 (16.0%) had filled a prescription for diagnosis of comorbid conditions. It was decided a of any CCPB and 122 (12.2%) had received calcitriol prior priori to include race, gender, and all health care utilizato onset of RRT. Only one patient received ergocalciferol, tion covariates in all models, as well as diabetes and but only after having filled a prescription for calcitriol. polycystic kidney disease as important classes of renal
The timing of the first of each of the four care measures comorbidity. Other comorbidities were included if they in relation to the day of first RRT is shown in Table 2 . remained significant at the P Ͻ 0.25 level in multivariate models (backward selection). We also tested for effect PTH testing modification between nephrologist contact and patient
We successfully matched on age and number of days age, as well as nephrologist contact and time between prior to RRT (ϭ index day) 86 individuals had iPTH index and first RRT. We calculated odds ratio (OR) as levels measured and 448 controls. Univariate conditional the measure of association, and 95% confidence intervals logistic regression models indicated that tested patients (95% CI).
were 68% more likely to have seen a nephrologist over For the second part of the analysis, we expanded on the the preceding 30 days than controls (OR ϭ 1.68; 95% CI, Cox proportional hazards models published in previous 1.02 to 2.76). Utilization of general practitioner services, work [7] , where death was the event of interest, and ceninternists, or hospital days over that time window were not different among cases and controls (Table 3) . Multisored patients at the earliest of the following: transplantavariate conditional logistic models controlling for demotion, loss to follow-up, or end of database. In addition to graphic characteristics and comorbid conditions revealed age, gender, race, and certain comorbidities (hypertenthat tested patients were more than twice as likely to sion, diabetes, congestive heart failure, coronary artery have seen a nephrologist during the previous month comdisease, malignancy), we included a variable depicting pared to patients who did not have testing for iPTH at late versus early nephrologist referral (Ͼ90 days vs. Յ90 the same number of days prior to RRT (OR ϭ 2.26; 95% days prior to RRT) and/or a covariate indicating whether CI, 1.35 to 3.80). Other health care utilization covariates a patient had received any of the four care measures
were not associated with case vs. control status. of interest prior to RRT (iPTH, vitamin D assessment, Vitamin D testing calcitriol, or CCPB prescription). For those, we calculated hazards ratio (HR) as the measure of association, Only 10 patients had laboratory assessment of vitamin and corresponding 95% CI. We used SAS 8.1 (The SAS D status prior to RRT, precluding any meaningful statistical analyses. Corporation, Cary, NC, USA) for all statistical analyses. Calcitriol prescriptions visit increased the odds of receiving the drug fivefold over patients who had not seen a nephrologist (OR ϭ 5.13; As above, we matched on age and index day 102 pa-95% CI, 3.17 to 8.32). Prior hospitalization was also tients who filled a prescription for calcitriol and 409 CKD predictive of starting calcitriol therapy (OR ϭ 2.81; 95% patients who had not done so. Univariate analyses showed CI, 1.59 to 4.98). that recipients of calcitriol were more than six times as likely to have seen a nephrologist over the previous month CCPB prescriptions than nonrecipients of this medication (OR ϭ 6.25; 95%
For this analysis, we were able to match 99 recipients of CI, 3.97 to 9.84) (see Table 4 ). As before, visits with CCPBs with 426 control patients. The univariate models general practitioners or internists were not associated with showed that recipients of a CCPB were 6.5 times as likely receipt of the medication. Hospitalization during the preto have seen a nephrologist within 30 days prior to filling vious 30 days also made patients more likely to have their first prescription than were nonrecipients of the received calcitriol (OR ϭ 3.20; 95% CI, 2.08 to 4.91).
drug (OR ϭ 6.46; 95% CI, 4.03 to 10.36) ( Table 5 ). The effect of nephrologist visits on the likelihood of Neither of the other physician visit covariates demonfilling a prescription for calcitriol remained robust in multivariate models. Having had a prior nephrologist strated such a univariate association with receipt of a Next, we evaluated whether presence of any calciumother), hypertension, diabetes, coronary artery disease, congestive heart failure, phosphate care indicator was associated with mortality malignancy in the first year of RRT. Using the 1004 patients with drug coverage, we first built a model similar to the one we published previously [11] and confirmed that late rather than early nephrologist referral (Յ90 vs. Ͼ90 days DISCUSSION prior to RRT) was associated with a 31% higher mortalWe evaluated several measures of calcium-phosphate ity rate (HR ϭ 1.31; 95% CI, 1.08 to 1.58) in these patients metabolism care (laboratory assessment of iPTH and after controlling for age, gender, race, presence of hypervitamin D levels and prescription of calcitriol or CCPBs) tension, coronary artery disease, congestive heart failure, in a cohort of patients with progressing CKD before and malignancy (Table 6 ). When replacing the late referonset of RRT. In contrast to recent studies that highral covariate with an indicator for any of the four care lighted the high prevalence of disturbances in the calmeasures studied herein, we found that the presence of cium-phosphate metabolism at relatively early stages of one or more of these care indicators (iPTH or vitamin CKD [13, 17] , we found each of the four care measures D measurement, or a prescription for calcitriol or any were performed in only a small proportion of patients. CCPB) was associated with a 38% reduction in the likeliOnly 3.4% of patients were tested for levels of iPTH, and hood of death in the first year of RRT compared to those vitamin D was assessed in even fewer patients (0.3%). who did not receive such care (HR ϭ 0.62; 95% CI, 0.49 Approximately 12.2% of patients filled a prescription to 0.80). When including both the late referral covariate for calcitriol prior to RRT and 16% for any CCPB. We and the calcium-phosphorus care indicator covariate in found a strong and temporally close relationship bethe same model, the effect of the latter did not change tween presence of a nephrologist visit and iPTH testing (HR ϭ 0.65; 95% CI, 0.51 to 0.84); however, the effect (OR ϭ 2.27; 95% CI, 1.35 to 3.80), patients' filling preof late referral on mortality was attenuated (HR ϭ 1.22; 95% CI, 1.00 to 1.48).
scriptions for calcitriol (OR ϭ 5.13; 95% CI, 3.17 to 8.32) and use of CCPBs (OR ϭ 6.60; 95% CI, 3.97 to 10.96). possibilities will have to be subjected to careful analysis.
Creative thinking and considerable experimentation will By contrast, we did not find any such associations bebe required to define the optimal mix of specialist-genertween prior general practitioner care, or with prior visits alist involvement in the care of such patients. with a nonnephrologist internist. These results indicate There are certain limitations to our study. Our analystrongly that nephrologists, rather than generalists or ses are based on large claims databases that may be internists of other subspecialties, are responsible for improne to miscoding or misclassification. It can be asportant domains of calcium-phosphate metabolism care sumed, however, that such misclassification will occur in patients with CKD. The interval between the first randomly rather than systematically, and, therefore, bias prescription for calcitriol and the initiation of RRT was any results toward the null. Furthermore, it is possible considerably longer than that between the first prescripthat we cannot capture all events of iPTH or vitamin tion of a CCPB and the start of dialysis. Although the D testing, if some patients were hospitalized when it current study was not designed to address issues of occurred. This would lead to an underestimation of the pathophysiology, the findings suggest that disturbances true percentage of patients screened. Similar biases are that lead to vitamin D therapy, such as hypocalcemia not possible with the drug-based analyses because paand/or elevated plasma PTH levels, occur earlier in the tients would fill a prescription right after discharge from course of progressive renal failure than those that trigger hospital care. However, there is the possibility that pathat use of phosphate-binding medications.
tients obtained over-the-counter preparations of calcium In studying 1-year mortality, we found that calciumcarbonate, which would be unaccounted for in our study. phosphate care interventions were associated with a 38% Also, we do not have any clinical information such as lower mortality on RRT compared to patients who did blood levels of biologic markers. It is possible that panot receive such attention of their calcium-phosphate metients who received the care measures under study may tabolism (OR ϭ 0.62; 95% CI, 0.49 to 0.80). All models have had more serious disease. However, patients who accounted for baseline differences in age, gender, race, received calcium-phosphate metabolism care prior to and important comorbidities. These findings suggest that first RRT had better survival compared to their countermanagement of calcium-phosphate metabolism is an imparts of similar age, demographics, and comorbidity. We portant mediator of the beneficial effect on mortality cannot rule out the possibility that rather than being the seen with timely nephrologist care in patients with CKD.
cause of the reduction in mortality noted, such care may These results have important policy implications. First, have been a marker for overall higher quality of care, specific care measures pertaining to calcium-phosphate and/or for patients who were more compliant or othermetabolism occur in a surprisingly small fraction of CKD wise attentive to their medical regimens. patients compared to what would be expected given crossWe conclude that there is considerable room for imsectional data about the frequency of such disturbances provement in the care of patients with CKD regarding [13, 34] . Second, our data indicate that management of their management of calcium-phosphate metabolism. calcium-phosphate metabolism in patients with CKD is Nephrologist consultation is associated with a higher frepredominantly nephrologist-driven. Third, we were able quency of use of laboratory and pharmaceutical meato demonstrate a strong association between calciumsures to manage this problem, and patients who receive phosphate metabolism care and improved mortality on such care of calcium-phosphate metabolism experience RRT. Improving this care domain in patients with CKD lower mortality once they initiate RRT. Given the manmay yield improved outcomes among patients on RRT, power limitations of available nephrologists, it seems probably even in patients with (advanced) CKD. This prudent to train nonnephrologists in managing this metahypothesis needs to be tested in further research. bolic disorder. Further research is necessary to confirm If this conclusion holds true, then it raises important our findings and to develop quality improvement proquestions about how best to care for all these patients.
grams to further the medical management of the vulneraNephrologist manpower projections for the care of patients ble population of patients with progressing CKD. on RRT alone are already falling short of the expected number of nephrologists available. It may be that educa-ACKNOWLEDGMENTS tion and training of nonnephrologists to provide testing 
